Elevate your Healthcare opportunity with DON
Companies we are currently assisting
Fundraising - Funding Secured through DON
Our team of experienced Business Development experts are assisting the CEO of NUAgo Therapeutics with an undisclosed funding round.
NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues.
Fundraising - Funding Secured through DON
Our team of experienced Business Development experts are assisting the CEO of Pristine Surgical with an undisclosed funding round.
DermaSensor is more than technology; it is a commitment to helping physicians detect skin cancer at the point of care with the first AI-powered medical device for all three common skin cancers.
Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.
Fundraising
Our team of experienced Business Development experts are assisting the CEO of Arcoris Bio with an undisclosed funding round.
Arcoris bio's mission is to empower personalized medicine with multiplex biomarker technologies.
Fundraising
Cellis is a European biotech company, with a focus in cell-based oncology therapy. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC) for the treatment of solid tumors. MDC is based on the ground-breaking discovery of the biologic TRAIN mechanism, which enables efficient and highly targeted delivery of a wide range of active moieties and compounds directly into the cytoplasm of cancer cells.
As a result, cancer cells are killed, and tumor masses shrink. MDC also changes the tumor microenvironment creating immune resistance to cancer growth. Preparation is underway to progress our technology to the first in human clinical trials in Q2 2025.
.png/:/cr=t:2.42%25,l:0%25,w:100%25,h:95.17%25/rs=w:1024,h:512,cg:true)
Fundraising and strategic partnerships
Preci-Health is revolutionizing the landscape of medical care by developing accessible, safe and virtually painless solutions for blood sampling and injections – anytime, anywhere. At the core of Preci-Health's groundbreaking offerings is our flagship product, EZdraw - a multi-tube blood sampler designed to shatter accessibility constraints within the market, not yet available commercially. Capable of multi-tube extraction with a single, high-volume draw – EZdraw is specifically compatible with standard vacutainers to match existing workflows in laboratories and other healthcare settings.
Fundraising and strategic partnerships
Amporin Pharmaceuticals is an emerging Swiss biotech company focused on the development of a breakthrough new class of small molecule membrane-protecting therapies for the treatment of neurodegenerative diseases – including ALS, Alzheimer's, Parkinson's, and many other degenerative diseases associated with protein misfolding and aggregation. Our vision is to transform the treatment of these diseases by specifically protecting vital cellular membranes against the toxic pore formation of soluble oligomers that are now believed to cause all these diseases.